Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2001-8-30
pubmed:abstractText
The Thomsen-Friedenreich (TF) antigen is a well-known human pan-carcinoma antigen. It represents a carbohydrate core disaccharide (Gal beta 1-3GalNAc) which is predominantly bound to mucin peptide cores. Its immunoreactivity depends on changes in glycosylation which lead to a reduction in the carbohydrate chain length and the exposure of core carbohydrates. In the present study, we investigated 208 gastric adenocarcinomas with respect to their immunohistochemical reactivity applying two monoclonal antibodies (MAbs). MAb specifically detecting TF antigen (A78-G/A7) and MAb BW835 were included. The latter reacts with a certain glycoform of the MUC1 peptide core, characterized by core-type glycans like TF. A78-G/A7 epitopes were detected in 68.8% and BW835 epitopes in 57.7% of the carcinomas. BW835 immunoreactivity correlated with the presence of lymph node metastases. Both A78-G/A7 and BW835 staining were significantly stronger in tubular/papillary cancer (WHO classification) and intestinal-type cancer according to Laurén. In univariate survival analyses of all patients studied, BW835 immunoreactivity was a marker of an unfavorable prognosis (p < 0.05). The presence of A78-G/A7 and BW835 epitopes exerted a negative effect on the subgroup of pTNM stage I carcinomas. These results indicate that TF and MUC1-TF immunoreactivity defines a 'high-risk' subgroup of stage I patients in gastric cancer.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0030-2414
pubmed:author
pubmed:copyrightInfo
Copyright 2001 S. Karger AG, Basel
pubmed:issnType
Print
pubmed:volume
61
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
147-55
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed-meshheading:11528254-Adenocarcinoma, pubmed-meshheading:11528254-Adult, pubmed-meshheading:11528254-Aged, pubmed-meshheading:11528254-Aged, 80 and over, pubmed-meshheading:11528254-Antibodies, Monoclonal, pubmed-meshheading:11528254-Antibody Specificity, pubmed-meshheading:11528254-Antigens, Neoplasm, pubmed-meshheading:11528254-Antigens, Tumor-Associated, Carbohydrate, pubmed-meshheading:11528254-Disease Progression, pubmed-meshheading:11528254-Epitopes, pubmed-meshheading:11528254-Female, pubmed-meshheading:11528254-Glycosylation, pubmed-meshheading:11528254-Humans, pubmed-meshheading:11528254-Immunoenzyme Techniques, pubmed-meshheading:11528254-Life Tables, pubmed-meshheading:11528254-Lymphatic Metastasis, pubmed-meshheading:11528254-Male, pubmed-meshheading:11528254-Middle Aged, pubmed-meshheading:11528254-Mucin-1, pubmed-meshheading:11528254-Multivariate Analysis, pubmed-meshheading:11528254-Neoplasm Proteins, pubmed-meshheading:11528254-Neoplasm Staging, pubmed-meshheading:11528254-Prognosis, pubmed-meshheading:11528254-Protein Isoforms, pubmed-meshheading:11528254-Protein Processing, Post-Translational, pubmed-meshheading:11528254-Retrospective Studies, pubmed-meshheading:11528254-Risk, pubmed-meshheading:11528254-Stomach Neoplasms, pubmed-meshheading:11528254-Survival Analysis, pubmed-meshheading:11528254-Tumor Markers, Biological
pubmed:year
2001
pubmed:articleTitle
Immunoreactivity of monoclonal antibody BW835 represents a marker of progression and prognosis in early gastric cancer.
pubmed:affiliation
Institute of Pathology, University of Cologne, Germany. s-e.baldus@uni-koeln.de
pubmed:publicationType
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't, Evaluation Studies